Wound

Corza Medical Named “Best Overall MedTech Company” in 8th Annual MedTech Breakthrough Awards Program

Retrieved on: 
Donnerstag, Mai 9, 2024
Medtech, Wound, Investment, Health, EHR, Surgeon, Electronic health record, Telehealth, Medical device, Patient, Medicine, Nursing

WESTWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corza Medical today announced that it has been selected as the winner of the “Best Overall MedTech Company” award in the 8th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies, and products in the global digital health and medical technology market.

Key Points: 
  • WESTWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corza Medical today announced that it has been selected as the winner of the “Best Overall MedTech Company” award in the 8th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough , an independent market intelligence organization that recognizes the top companies, technologies, and products in the global digital health and medical technology market.
  • Corza Medical provides healthcare professionals with a platform of surgical technologies and features industry-leading brands.
  • The Corza Medical Biosurgery unit provides best-in-class, innovative technology that helps control bleeding during surgery.
  • “Corza Medical is our “MedTech Company of the Year” for its high-performance technologies and its focus on customer service.

GREENSTEIN & MILBAUER, LLP FILES MULTIPLE TRUCK ACCIDENT LAWSUITS

Retrieved on: 
Dienstag, April 30, 2024
Accident, Burns, LLP, Supreme court, Pepsi, Neck, Death, Fracture, Injury, Amazon, TBI, Amputation, Internal bleeding, Crash, Wound, Head, Traumatic brain injury, Tetraplegia, Road

NEW YORK, April 30, 2024 /PRNewswire/ -- Greenstein & Milbauer, LLP, a personal injury law firm based in New York City ( www.nyclawfirm.com ) has filed multiple truck accident lawsuits..

Key Points: 
  • NEW YORK, April 30, 2024 /PRNewswire/ -- Greenstein & Milbauer, LLP, a personal injury law firm based in New York City ( www.nyclawfirm.com ) has filed multiple truck accident lawsuits..
  • Robert Greenstein, a partner at Greenstein & Milbauer, LLP, states, "Accidents involving large trucks are much more complicated than many other traffic accidents.
  • fatal truck accidents)
    If you were injured in a truck accident, you can recover compensation for your injuries and damages.
  • The New York City truck accident lawyers at Greenstein & Milbauer, LLP, can help you recover the compensation you deserve.

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences

Retrieved on: 
Donnerstag, April 25, 2024
Symposium, WHS, Patient, SAWC, Wound, European Wound Management Association, Wound healing, EWMA, Nursing

YAVNE, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, announced today that recent clinical data from EscharEx® Phase II studies will be presented throughout May 2024 at the largest, most prestigious annual meetings in the field of chronic wound care: the European Wound Management Association (EWMA), the Wound Healing Society (WHS), and the Symposium on Advanced Wound Care (SAWC).

Key Points: 
  • The oral presentations on EscharEx will include:
    Comparative data of EscharEx vs. SANTYL® that demonstrate EscharEx’s superiority over the current leading enzymatic debridement agent
    New analyses from the ChronEx phase II study, showing high correlation between wound bed preparation and wound healing
    These data indicate that EscharEx could substantially improve wound care for patients with debilitating chronic wounds, providing significant benefits over the current standard of care.
  • Additionally, the findings support the design and endpoints of the upcoming Phase III study, which is expected to begin in the second half of 2024.
  • "We are delighted to present the results of additional analyses from EscharEx Phase II studies in chronic hard-to-heal wounds, including the positive comparative data with SANTYL®, the current dominant standard of care for enzymatic debridement," said Dr. Robert J. Snyder, Chief Medical Officer of MediWound.
  • "With its robust efficacy, favorable safety profile, and multimodal mechanistic effects demonstrated in these Phase II studies, we believe that EscharEx can significantly advance wound care and has the potential to become a major player in the global wound care market."

MPM Medical Launching New Wound Care Products and Branding

Retrieved on: 
Dienstag, April 23, 2024
Aloe, Wound healing, Safety, CPH, Abstract, Aloe vera, Granulation tissue, Acid, CIC, WHS, Medicine, MPH, SAWC, Wound, Associate, Lidocaine, Nursing

MESQUITE, Texas, April 23, 2024 /PRNewswire/ -- MPM Medical, a pioneer in the advanced wound care industry, will participate in the 2024 Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society (WHS) held May 14-18 in Orlando. As the largest gathering of multidisciplinary wound care clinicians in the United States, this year's symposium will be a momentous event for MPM Medical.

Key Points: 
  • MESQUITE, Texas, April 23, 2024 /PRNewswire/ -- MPM Medical , a pioneer in the advanced wound care industry, will participate in the 2024 Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society (WHS) held May 14-18 in Orlando.
  • As the largest gathering of multidisciplinary wound care clinicians in the United States, this year's symposium will be a momentous event for MPM Medical.
  • Attendees are invited to stop by the MPM Medical booth #633 for product demonstrations from our certified wound care experts or to request product samples.
  • In addition to the expanded range of advanced wound care products, MPM Medical's booth will be showcasing the company's new corporate branding and tagline, Medical Products that Matter™.

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Retrieved on: 
Donnerstag, März 21, 2024
Burn, Tax, Debridement, Patient, EWMA, Bank statement, Eschar, Investment, SAWC, Therapy, Depreciation, European Commission, Phase, BCC, Research, Supplement, Wound, EMA, GMP, HERE, Safety, CMS, BLA, Eastern Time Zone, Food, Bromelain (pharmacology), WBP, Development, PMI, WHS, Adjustment, FDA, BMCI, Forecasting, Symposium, Incidence, BSV, Basal-cell carcinoma, Operating cost, European Wound Management Association, Table, Event, Medicare, Pharmaceutical industry

YAVNE, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Revenue: Revenue for the fourth quarter 2023 was $5.3 million, compared to $11.6 million in the fourth quarter of 2022.
  • Research and development expenses in the fourth quarter 2023 were $1.8 million compared to $2.7 million in the fourth quarter of 2022.
  • Selling, general, and administrative expenses in the fourth quarter 2023 were $2.8 million, compared to $3.0 million in the fourth quarter of 2022.
  • Operating Results: Operating loss in the fourth quarter of 2023 was $3.9 million, compared to an operating profit of $2.1 million in the fourth quarter of 2022.

MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing

Retrieved on: 
Mittwoch, März 20, 2024
Cell adhesion, Ulcer, Wound, Partnership, Patient, Trauma, Surgeon, Wound healing, Collagen, Surgery

Commenting on this agreement, Joseph H. Capper, MIMEDX Chief Executive Officer, stated, “We are excited to announce the formation of this partnership with Regenity and believe it is an important step toward achieving our long-term growth plan.

Key Points: 
  • Commenting on this agreement, Joseph H. Capper, MIMEDX Chief Executive Officer, stated, “We are excited to announce the formation of this partnership with Regenity and believe it is an important step toward achieving our long-term growth plan.
  • As we have stated, one of our strategic priorities is to augment our best-in-class placental-derived product portfolio with xenografts and/or synthetic skin substitutes in order to meet the needs of a greater number of customers, domestically and abroad.
  • The collagen in this product serves as a dressing that allows for cell adhesion and migration into the wound site and supports wound healing.
  • “Additionally, we look forward to partnering with Regenity and leveraging their expertise to bring other products in our pipeline to market in the future.

National PTA and Everytown for Gun Safety Announce New Collaboration in the Fight to Protect Kids from Gun Violence

Retrieved on: 
Donnerstag, März 7, 2024
CAE, Violence, Everytown for Gun Safety, Research, Wound, Gun, Sale, Parent, Curriculum, Life, Conference, Bipartisan Background Checks Act, Safety, School, Fear, Background check, Death, PTA, Policy, Legislation, Congress, Child, Assault weapons ban, Firearm, Nursing

ALEXANDRIA, Va., March 7, 2024 /PRNewswire/ -- With firearm injury now the leading cause of death for children under the age of 19, National PTA and Everytown for Gun Safety have joined forces to help protect children and youth from gun violence and save lives. Through the alliance, National PTA and Everytown will develop tools and resources to empower parent leaders nationwide to influence policy and planning decisions related to gun violence prevention and school safety and preparedness. The announcement of the alliance was made during National PTA's 2024 Legislative Conference in the nation's capital.

Key Points: 
  • Through the alliance, National PTA and Everytown will develop tools and resources to empower parent leaders nationwide to influence policy and planning decisions related to gun violence prevention and school safety and preparedness.
  • As part of the alliance, National PTA and Everytown commissioned a national survey exploring parents' mindsets around school safety and gun violence prevention and policy.
  • Gun safety is important to most parents and over two-thirds would vote for the candidate who supports strengthening gun safety laws.
  • "PTA members across the country have played a critical role in advocating for common sense solutions to gun violence.

JUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA Approval

Retrieved on: 
Dienstag, März 5, 2024
Senior, Tenderness, Infection, Dizziness, AbbVie, XC, Lidocaine, Swelling, Exercise, Skin, Pregnancy, History, Cyst, Red, HIV/AIDS, Trial of the century, Allergy, Social media, Incidence, Neck, Dermatology, Aspirin, Pain, Forehead, Stroke, Hyaluronic acid, Pimple, Pigment, Ibuprofen, Scar, Rash, Anaphylaxis, Chin, Learning, Weakness, Safety, Filler (linguistics), DSM-IV codes, Hypoesthesia, Clinical trial, Paratriathlon, Bleeding, Face, Jaw, ABBV, Injection, Bruise, AMI, Inflammation, FDA, TSR, U.S. FDA, Confusion, Risk, Steroid, Patient, Tell, Wound, Gram, HIV, Cheek

IRVINE, Calif., March 5, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM® VOLUMA® XC for injection in the temple region to improve moderate to severe temple hollowing in adults over the age of 21.1 JUVÉDERM® VOLUMA® XC is the first and only hyaluronic acid (HA) dermal filler to receive U.S. FDA approval for the improvement of moderate to severe temple hollowing with results lasting up to 13 months with optimal treatment.*1

Key Points: 
  • *1
    "The approval of JUVÉDERM® VOLUMA® XC to treat temple hollows further demonstrates Allergan Aesthetics commitment to innovation and addressing patient needs," said Carrie Strom, President, Allergan Aesthetics and Senior Vice President, AbbVie.
  • "This is the first U.S. FDA approval of a hyaluronic acid dermal filler for use in the upper face and addresses a real unmet need for patients."
  • The safety of JUVÉDERM® VOLUMA® XC in patients with a history of excessive scarring or pigmentation disorders has not been studied.
  • To report a side effect with any product in the JUVÉDERM® Collection, please call the Allergan® Product Support Department at 1‑877‑345‑5372.

The Wound Pros Launches Wound Care Without Walls Program in Nigeria

Retrieved on: 
Montag, März 4, 2024
Psoriasis, Acne, LOS, FDA, Wound, Bacteria, Burns, Medicine, WCWW, Dermatitis, Gram-negative bacteria

LOS ANGELES, March 4, 2024 /PRNewswire/ -- Dr. Chris Otiko, co-founder and corporate treasurer at The Wound Pros: https://www.thewoundpros.com, was recently in Abuja, Nigeria's capital, to launch the company's Wound Care Without Walls (WCWW) program and introduce Tetracyte.

Key Points: 
  • The Wound Pros extends its healing services into Nigeria.
  • Promotes Tetracyte product
    LOS ANGELES, March 4, 2024 /PRNewswire/ -- Dr. Chris Otiko, co-founder and corporate treasurer at The Wound Pros: https://www.thewoundpros.com , was recently in Abuja, Nigeria's capital, to launch the company's Wound Care Without Walls (WCWW) program and introduce Tetracyte.
  • Otiko was accompanied by Texas resident Adebola Adefuye, clinical supervisor for The Wound Pros' Complex Wound Management Team.
  • Otiko and Adebola also had strategy discussions with Wound Pros employees in Nigeria, focusing on marketing avenues to launch product sales in Nigeria.

Cinesteam® Is Using Cinnamon to Improve Malodorous Smells

Retrieved on: 
Donnerstag, Februar 29, 2024
Caregiver, Lead poisoning, Embarrassment, Quality of life, Wound, Social behavior, Business, Patient, Coffee, Taste, Social isolation, Nausea, Appetite, Nursing

FORT LAUDERDALE, Fla., Feb. 29, 2024 /PRNewswire/ -- Malodorous wounds are severe chronic wounds that generate strong, unpleasant odors on a consistent basis. It's easy for those who have not personally experienced or cared for someone with a malodorous wound to under prioritize the issue. They often categorize the condition as little more than an unfortunate side effect that can create unpleasant experiences. But that couldn't be further from the truth.

Key Points: 
  • It's easy for those who have not personally experienced or cared for someone with a malodorous wound to under prioritize the issue.
  • "Side effects like malodorous smells can compromise an individual's entire quality of life," explains Clémence Desjardin, Director of Operations and Business Development at Cemag Care.
  • In the end, cinnamon proved a uniquely effective way to adsorb smells and replace them with good-smelling alternatives.
  • It is a natural-based dressing designed to restore control of the healing process by enabling patients and caregivers to reduce bad smells from malodorous wounds and improve quality of life.